|1.||Kobunai, T: 2 articles (11/2001 - 05/2000)|
|2.||Yamada, Y: 2 articles (11/2001 - 05/2000)|
|3.||Fujimoto, Shuichi: 1 article (10/2007)|
|4.||Igarashi, Tomonori: 1 article (01/2005)|
|5.||Izumi, Hiroto: 1 article (01/2005)|
|6.||Itoh, Hideaki: 1 article (01/2005)|
|7.||Yoshida, Takeshi: 1 article (01/2005)|
|8.||Niina, Ichiro: 1 article (01/2005)|
|9.||Chijiiwa, Kazuo: 1 article (01/2005)|
|10.||Wakasugi, Tetsuro: 1 article (01/2005)|
04/01/2001 - "We conducted a phase I study to determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of TAS-103 when administered on a weekly schedule to patients with advanced cancer. "
04/01/2001 - "Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer."
10/01/2007 - "These results strongly suggest that TAS-103 will be expected to show excellent antitumor activities against a wide range of human tumors."
10/01/2002 - "These results suggest that liposomal TAS-103 is useful for cancer therapy."
10/01/2002 - "To enhance anti-tumor efficacy and to reduce the side effects of the agent, liposomalization of TAS-103 was performed. "
|2.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/01/1999 - "Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells."
01/01/1999 - "These results suggest that the concomitant use of TAS-103 and cisplatin has a greater cytotoxic effect on cancer cells than single drug use, and may provide a beneficial effect in the treatment of small-cell lung cancer."
01/01/1999 - "Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer."
01/01/1999 - "We examined the effect of a novel topoisomerase I and II (topo I and II) inhibitor, TAS-103, on P-glycoprotein (P-gp)-expressing and -nonexpressing drug-resistant human small-cell lung cancer (SCLC) cells in vitro and in vivo. "
|3.||Lewis Lung Carcinoma
10/01/2002 - "To evaluate the anti-tumor efficacy of liposomal TAS-103, the growth inhibition against Lewis lung carcinoma cells in vitro and the therapeutic efficacy against solid tumor-bearing mice in vivo were examined. "
10/01/2002 - "Liposomal TAS-103 showed strong cytotoxic effect against Lewis lung carcinoma cells in a dose dependent manner and effectively suppressed solid tumor growth accompanying longer survival time of tumor-bearing mice in comparison with the mice treated with free TAS-103. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
|5.||Colorectal Neoplasms (Colorectal Cancer)
11/01/2001 - "The aim of the present study was to investigate the antitumor activity of TAS-103 by the MTT assay in human highly-purified and freshly-isolated colorectal cancer cells. "
11/01/2001 - "TAS-103 showed the strongest antitumor activity among the conventional anticancer agents for colorectal cancer (p<0.05). "
11/01/2001 - "To our knowledge, this is the first data concerning the antitumor activity of TAS-103 in highly-purified and isolated human colorectal cancer cells. "
11/01/2001 - "In vitro antitumor activity of TAS-103 against freshly-isolated human colorectal cancer."
11/01/2001 - "In conclusion, according to this data, TAS-103 may be useful in the chemotherapy of colorectal cancer."
|1.||trioctyl phosphine oxide (TOPO)
|2.||Type I DNA Topoisomerases (Topoisomerase I)
|4.||DNA (Deoxyribonucleic Acid)
|8.||Adenocarcinoma of lung
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)